Shares of Endocyte, Inc. (NASDAQ:ECYT) reached a new 52-week high and low during mid-day trading on Tuesday . The stock traded as low as $15.45 and last traded at $15.14, with a volume of 64731 shares trading hands. The stock had previously closed at $14.42.

Several analysts have issued reports on ECYT shares. BidaskClub upgraded shares of Endocyte from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 4th. ValuEngine upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Zacks Investment Research lowered shares of Endocyte from a “buy” rating to a “hold” rating in a research report on Friday, May 11th. Cowen upgraded shares of Endocyte from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 27th. Finally, Wells Fargo & Co assumed coverage on shares of Endocyte in a research report on Friday, March 9th. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $9.00.

The firm has a market capitalization of $988.31 million, a price-to-earnings ratio of -14.58 and a beta of 0.59.

Endocyte (NASDAQ:ECYT) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. The company had revenue of $0.02 million during the quarter. Endocyte had a negative net margin of 70,510.81% and a negative return on equity of 34.20%. equities research analysts predict that Endocyte, Inc. will post -0.76 earnings per share for the current fiscal year.

In other news, VP Christopher P. Leamon sold 13,089 shares of the stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $15.06, for a total transaction of $197,120.34. Following the completion of the sale, the vice president now directly owns 130,381 shares in the company, valued at $1,963,537.86. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.65% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. venBio Select Advisor LLC bought a new position in Endocyte in the first quarter worth about $51,769,000. VHCP Management II LLC bought a new position in Endocyte in the first quarter worth about $39,087,000. BlackRock Inc. raised its stake in Endocyte by 50.2% in the first quarter. BlackRock Inc. now owns 1,710,716 shares of the biopharmaceutical company’s stock worth $15,551,000 after buying an additional 571,925 shares in the last quarter. Perceptive Advisors LLC bought a new position in Endocyte in the fourth quarter worth about $6,213,000. Finally, Rock Springs Capital Management LP bought a new position in Endocyte in the first quarter worth about $6,136,000. 67.44% of the stock is owned by institutional investors.

Endocyte Company Profile

Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.